Esophagus | Larynx | Lip, Oral Cavity and Pharynx | Thyroid | Phase I, Phase I

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Volunteers
Health Professionals

What is the purpose of this trial?

This is a multi center, open-label, phase 1 dose escalation and expansion study evaluating the safety, anti-tumor effect, and immunogenicity of CUE-101 in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

Trial with
Cue Biopharma, Inc.
Ages
18 years and older
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Jenny Remetta

jenny.remetta@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Barbara Burtness, MD
Professor of Medicine (Medical Oncology); Chief Translational Research Officer, Yale Cancer Center; Chief, Head and Neck Cancers/Sarcoma; Co-Leader, Developmental Therapeutics, Yale Cancer Center; Associate Cancer Center Director for Translational Research, Yale Cancer Center

Sub-Investigators

Last Updated
02/15/2023
Study HIC
#2000026098